Thaindian News

November 17, 2010 (Pen Men at Work): A ground-breaking ‘pilot research’ named Apollo from the Netherlands has detected that stem cells, captured from waistline fat, can be utilized to mitigate cardiological attacks and save lives. The scientists in the study inserted the stem cells from the waistline fat tissue (spare tyre) into the heart of the coronary patients, with the ramifications being the diminishment of damage levels, heightened blood passage and enhancement in the organs’ pumping capacity. In this research project, a total of 14 individuals consisting of three females and 11 males had participated, with each of them having endured a cardiological attack recently. Ten patients were the recipients of stem cell infusion while four obtained a dummy ‘placebo’ insertion.

Liposuction is a widespread cosmetic treatment utilized to extricate fattiness from the individuals’ waistlines. It was employed in this research to extract up to 250 cubic centimeters of fat from the patients’ tummies. From each sample, the canvassers segregated and pulled out 20 million mature stem cells, which were regenerative cells with the capability to become more than one sort of tissue. 10 minutes were required to inject the stem cells into the heart of each patient, with the consequence six months later being that the 10 patients exhibited a considerable 3.5% betterment in cardiological perfusion, which is the heart’s capacity to obtain oxygenated blood. The patients, who received the injection of stem cells, also demonstrated a 5.7% augmentation in the quantity of blood pumped out by their cardiological left ventricle chamber. Their recovery was better than the patients in the ‘placebo’ group

The research, of which the chief was Dr. Duckers, from the Erasmus University Medical Centre located in Rotterdam, has suggested that these cells could be procured harmlessly and inserted into the heart of a patient subsequent to a sharp cardiological attack. The research has also revealed that the stem cells did not intervene harmfully in the blood flow and were not connected to any perilous alterations in the cardiological rhythm. Generally, the quantity of injured cardiological muscles in the treated patients was decreased from 31.6% to 15.4%. In the non-treated list of patients, the extent of cardiological damage remained the same.

These revelations have been offered at the American Heart Association’s Scientific Sessions in Chicago. Dr.Duckers has bigger ambitions for which he has already commenced work. He intends to execute a larger follow-up trial, referred to as ‘Advance’, which will hire 375 patients from 35 European centers, whose cardiological status will be monitored six months subsequent to treatment. This examination will concentrate on patients, victimized by heart attacks, who possess a ‘left ventricle ejection fraction’ (LVEF) of lower than 45%, the LVEF being an indicator of the cardiological pumping performance. 40% of these patients will procure 20 million stem cells while another 40 per cent will attain a more substantial dose of 30 million cells. 20 per cent of the patients will constitute the placebo group.